Disease Overview
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.
ACTA2
Pipeline results not yet available for this target. Run the pipeline to populate.
APOB
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| DEXAMETHASONE | ? unclear | Mechanistic | DGIdb | |
| L-644,698 | ↑ activates | Mechanistic | DGIdb | |
| INCLISIRAN | ? unclear | Mechanistic | DGIdb | |
| REVERSE TRANSCRIPTASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| ZK118182 | ↑ activates | Mechanistic | DGIdb | |
| RS 93520 | ↑ activates | Mechanistic | DGIdb | |
| RIVAROXABAN | ? unclear | Mechanistic | DGIdb | |
| ONO-AE3-237 | ↓ inhibits | Mechanistic | DGIdb | |
| ALPROSTADIL | ↑ activates | Mechanistic | DGIdb | |
| Δ12-PGJ2 | ↑ activates | Mechanistic | DGIdb | |
| DINOPROSTONE | ↑ activates | Mechanistic | DGIdb | |
| PGJ2 | ↑ activates | Mechanistic | DGIdb | |
| LOVASTATIN | ? unclear | Mechanistic | DGIdb | |
| SQ-27986 | ↑ activates | Mechanistic | DGIdb | |
| TG11-77 | ↓ inhibits | Mechanistic | DGIdb | |
| FENOFIBRATE MICRONIZED | ? unclear | Mechanistic | DGIdb | |
| CLOPROSTENOL | ↑ activates | Mechanistic | DGIdb | |
| U46619 | ↑ activates | Mechanistic | DGIdb | |
| TG6-129 | ↓ inhibits | Mechanistic | DGIdb | |
| APIXABAN | ? unclear | Mechanistic | DGIdb | |
| DEHYDRATED ALCOHOL | ? unclear | Mechanistic | DGIdb | |
| BWA868C | ↓ inhibits | Mechanistic | DGIdb | |
| ZK110841 | ↑ activates | Mechanistic | DGIdb | |
| MIPOMERSEN | ? unclear | Mechanistic | DGIdb | |
| CHOLESTYRAMINE RESIN | ? unclear | Mechanistic | DGIdb | |
| EPIGALLOCATECHIN GALLATE | ? unclear | Mechanistic | DGIdb | |
| ATORVASTATIN CALCIUM TRIHYDRATE | ? unclear | Mechanistic | DGIdb | |
| DINOPROST | ↑ activates | Mechanistic | DGIdb | |
| [3H]BWA868C | ↓ inhibits | Mechanistic | DGIdb | |
| HEPARIN | ? unclear | Mechanistic | DGIdb | |
| S-5751 | ↓ inhibits | Mechanistic | DGIdb | |
| PRAVASTATIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| BW 245C | ↑ activates | Mechanistic | DGIdb | |
| LOMITAPIDE MESYLATE | ? unclear | Mechanistic | DGIdb | |
| L-888,291 | ↑ activates | Mechanistic | DGIdb | |
| QUERCETIN | ? unclear | Mechanistic | DGIdb | |
| AH6809 | ↓ inhibits | Mechanistic | DGIdb | |
| 15-DEOXY-Δ12,14-PGJ2 | ↑ activates | Mechanistic | DGIdb | |
| TRIFLUOPERAZINE | ? unclear | Mechanistic | DGIdb | |
| PGD2 | ↑ activates | Mechanistic | DGIdb |
Showing top 40 of 102 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| JNJ1661010 | ↓ inhibits | Mechanistic | DGIdb | |
| ADALIMUMAB | ? unclear | Mechanistic | DGIdb | |
| LY2077855 | ↓ inhibits | Mechanistic | DGIdb | |
| OL135 | ↓ inhibits | Mechanistic | DGIdb | |
| WARFARIN | ? unclear | Mechanistic | DGIdb | |
| ASP8477 | ↓ inhibits | Mechanistic | DGIdb | |
| URB597 | ↓ inhibits | Mechanistic | DGIdb | |
| ROSUVASTATIN | ? unclear | Mechanistic | DGIdb |
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| ZILTIVEKIMAB | ~ modulates | Mechanistic | DGIdb | |
| CHINESE HERBS | ? unclear | Mechanistic | DGIdb | |
| PF-04236921 | ↓ inhibits | Mechanistic | DGIdb | |
| MRA 003 US | ↓ inhibits | Mechanistic | DGIdb | |
| SIGNAL TRANSDUCTION INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| BINETRAKIN | ? unclear | Mechanistic | DGIdb | |
| IBUDILAST | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| SILTUXIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| METRONIDAZOLE | ? unclear | Mechanistic | DGIdb | |
| CLAZAKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| GALLIUM NITRATE | ? unclear | Mechanistic | DGIdb | |
| INTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| DULOXETINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| MEDI-5117 | ↓ inhibits | Mechanistic | DGIdb | |
| GEMFIBROZIL | ? unclear | Mechanistic | DGIdb | |
| BIAFINE CREAM | ? unclear | Mechanistic | DGIdb | |
| ETANERCEPT | ? unclear | Mechanistic | DGIdb | |
| ELSILIMOMAB | ↓ inhibits | Mechanistic | DGIdb | |
| SAQUINAVIR | ? unclear | Mechanistic | DGIdb | |
| INFLIXIMAB | ? unclear | Mechanistic | DGIdb | |
| LINEZOLID | ? unclear | Mechanistic | DGIdb | |
| IFOSFAMIDE | ? unclear | Mechanistic | DGIdb | |
| OLOKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| HMG-COA REDUCTASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| MIDOSTAURIN | ? unclear | Mechanistic | DGIdb | |
| SELENIUM | ? unclear | Mechanistic | DGIdb | |
| SIRUKUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| ECHINACEA PREPARATION | ? unclear | Mechanistic | DGIdb | |
| ENZYME INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| FENOFIBRATE MICRONIZED | ? unclear | Mechanistic | DGIdb | |
| VITAMIN K | ? unclear | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2A | ? unclear | Mechanistic | DGIdb | |
| RIBAVIRIN | ? unclear | Mechanistic | DGIdb | |
| VITAMIN A PALMITATE | ? unclear | Mechanistic | DGIdb | |
| ARSENIC TRIOXIDE | ? unclear | Mechanistic | DGIdb | |
| DIHYDROSPHINGOSINE | ? unclear | Mechanistic | DGIdb | |
| LEVOFLOXACIN ANHYDROUS | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 173 agents ranked by evidence tier.
LDLR
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| HMG-COA REDUCTASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| GLUCAGON (RDNA) | ? unclear | Mechanistic | DGIdb | |
| ATENOLOL | ? unclear | Mechanistic | DGIdb | |
| VITAMIN A | ? unclear | Mechanistic | DGIdb | |
| COLESTIPOL HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| HEPARIN CALCIUM | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL233611 | ? unclear | Mechanistic | DGIdb | |
| TRIBUTYRIN | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT TRANSFORMING GROWTH FACTOR | ? unclear | Mechanistic | DGIdb | |
| CHOLESTYRAMINE RESIN | ? unclear | Mechanistic | DGIdb | |
| GEMFIBROZIL | ? unclear | Mechanistic | DGIdb | |
| EPOETIN ALFA | ? unclear | Mechanistic | DGIdb | |
| TETRACYCLINE | ? unclear | Mechanistic | DGIdb | |
| HALOPERIDOL DECANOATE | ? unclear | Mechanistic | DGIdb | |
| MIPOMERSEN | ? unclear | Mechanistic | DGIdb | |
| PHYTOESTROGEN | ? unclear | Mechanistic | DGIdb | |
| ANTIVIRAL AGENT | ? unclear | Mechanistic | DGIdb | |
| FAT EMULSION | ? unclear | Mechanistic | DGIdb | |
| VERAPAMIL | ? unclear | Mechanistic | DGIdb | |
| LOMITAPIDE MESYLATE | ? unclear | Mechanistic | DGIdb | |
| SOY PROTEIN ISOLATE | ? unclear | Mechanistic | DGIdb | |
| ANTIBIOTIC | ? unclear | Mechanistic | DGIdb | |
| BUTYRIC ACID | ? unclear | Mechanistic | DGIdb | |
| ACTH | ? unclear | Mechanistic | DGIdb | |
| ALIROCUMAB | ? unclear | Mechanistic | DGIdb | |
| INCLISIRAN | ? unclear | Mechanistic | DGIdb | |
| LOVASTATIN | ? unclear | Mechanistic | DGIdb | |
| ACETYLCYSTEINE | ? unclear | Mechanistic | DGIdb | |
| ROSUVASTATIN | ? unclear | Mechanistic | DGIdb | |
| PRAVASTATIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| EVINACUMAB | ? unclear | Mechanistic | DGIdb | |
| CHEMBL114890 | ↑ activates | Mechanistic | 700.0 nM (EC50) | ChEMBL |
| CHEMBL114705 | ↑ activates | Mechanistic | 1200.0 nM (EC50) | ChEMBL |
| CHEMBL115304 | ↑ activates | Mechanistic | 1300.0 nM (EC50) | ChEMBL |
| CHEMBL324616 | ↑ activates | Mechanistic | 700.0 nM (EC50) | ChEMBL |
| CHEMBL115205 | ↑ activates | Mechanistic | 4000.0 nM (EC50) | ChEMBL |
| CHEMBL112449 | ↑ activates | Mechanistic | 1000.0 nM (EC50) | ChEMBL |
| CHEMBL419400 | ↑ activates | Mechanistic | 7000.0 nM (EC50) | ChEMBL |
| CHEMBL419763 | ↑ activates | Mechanistic | 1700.0 nM (EC50) | ChEMBL |
| CHEMBL419042 | ↑ activates | Mechanistic | 2000.0 nM (EC50) | ChEMBL |
Showing top 40 of 48 agents ranked by evidence tier.
NOS3
Pipeline results not yet available for this target. Run the pipeline to populate.
PCSK9
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ALIROCUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| ONGERICIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| TAFOLECIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| LOMITAPIDE MESYLATE | ? unclear | Mechanistic | DGIdb | |
| EVOLOCUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| RG-7652 | ↓ inhibits | Mechanistic | DGIdb | |
| BOCOCIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| FROVOCIMAB | ? unclear | Mechanistic | DGIdb | |
| RALPANCIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| LERODALCIBEP | ↓ inhibits | Mechanistic | DGIdb | |
| INCLISIRAN | ? unclear | Mechanistic | DGIdb | |
| INCLISIRAN SODIUM | ? unclear | Mechanistic | Open Targets | |
| DIPHENYL BORINIC ACID | ↓ inhibits | Mechanistic | 30000.0 nM (Ki) | ChEMBL |
| PHENYL BUTYL BORINIC ACID | ↓ inhibits | Mechanistic | 1000.0 nM (Ki) | ChEMBL |
| CHEMBL4107804 | ↓ inhibits | Mechanistic | 3200.0 nM (IC50) | ChEMBL |
| CHEMBL4107907 | ↓ inhibits | Mechanistic | 1700.0 nM (IC50) | ChEMBL |
| CHEMBL4114159 | ↓ inhibits | Mechanistic | 800.0 nM (IC50) | ChEMBL |
| CHEMBL4108338 | ↓ inhibits | Mechanistic | 1500.0 nM (IC50) | ChEMBL |
| CHEMBL4107714 | ↓ inhibits | Mechanistic | 1500.0 nM (IC50) | ChEMBL |
| CHEMBL4110311 | ↓ inhibits | Mechanistic | 9500.0 nM (IC50) | ChEMBL |
| CHEMBL4107559 | ↓ inhibits | Mechanistic | 1800.0 nM (IC50) | ChEMBL |
| CHEMBL4114106 | ↓ inhibits | Mechanistic | 1500.0 nM (IC50) | ChEMBL |
| CHEMBL4109097 | ↓ inhibits | Mechanistic | 11700.0 nM (IC50) | ChEMBL |
| CHEMBL4108330 | ↓ inhibits | Mechanistic | 2300.0 nM (IC50) | ChEMBL |
| CHEMBL4109114 | ↓ inhibits | Mechanistic | 4500.0 nM (IC50) | ChEMBL |
| CHEMBL3961039 | ↓ inhibits | Mechanistic | 7300.0 nM (IC50) | ChEMBL |
| CHEMBL4112247 | ↓ inhibits | Mechanistic | 10700.0 nM (IC50) | ChEMBL |
| CHEMBL4109308 | ↓ inhibits | Mechanistic | 800.0 nM (IC50) | ChEMBL |
| CHEMBL4109014 | ↓ inhibits | Mechanistic | 11820.0 nM (IC50) | ChEMBL |
| CHEMBL4108567 | ↓ inhibits | Mechanistic | 3800.0 nM (IC50) | ChEMBL |
| CHEMBL4111131 | ↓ inhibits | Mechanistic | 18000.0 nM (IC50) | ChEMBL |
| CHEMBL4115372 | ↓ inhibits | Mechanistic | 1700.0 nM (IC50) | ChEMBL |
| CHEMBL4106481 | ↓ inhibits | Mechanistic | 3050.0 nM (IC50) | ChEMBL |
| CHEMBL4108186 | ↓ inhibits | Mechanistic | 5610.0 nM (IC50) | ChEMBL |
| CHEMBL4115360 | ↓ inhibits | Mechanistic | 5800.0 nM (IC50) | ChEMBL |
| CHEMBL4114503 | ↓ inhibits | Mechanistic | 25300.0 nM (IC50) | ChEMBL |
| CHEMBL4108540 | ↓ inhibits | Mechanistic | 2970.0 nM (IC50) | ChEMBL |
| CHEMBL4109409 | ↓ inhibits | Mechanistic | 5750.0 nM (IC50) | ChEMBL |
| CHEMBL4109932 | ↓ inhibits | Mechanistic | 14300.0 nM (IC50) | ChEMBL |
| CHEMBL4106569 | ↓ inhibits | Mechanistic | 16800.0 nM (IC50) | ChEMBL |
Showing top 40 of 170 agents ranked by evidence tier.
TET2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| SELINEXOR | ? unclear | Mechanistic | DGIdb | |
| AZACITIDINE | ? unclear | Mechanistic | DGIdb | |
| RITUXIMAB | ? unclear | Mechanistic | DGIdb | |
| QUIZARTINIB | ? unclear | Mechanistic | DGIdb | |
| TALAZOPARIB | ? unclear | Mechanistic | DGIdb | |
| HYDROCHLOROTHIAZIDE | ? unclear | Mechanistic | DGIdb | |
| ELTANEXOR | ? unclear | Mechanistic | DGIdb | |
| OLAPARIB | ? unclear | Mechanistic | DGIdb | |
| DASATINIB ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| VEMURAFENIB | ? unclear | Mechanistic | DGIdb | |
| DOXORUBICIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| HYDROXYUREA | ? unclear | Mechanistic | DGIdb | |
| CHEMBL4457636 | ↓ inhibits | Mechanistic | 73000.0 nM (IC50) | ChEMBL |
| CHEMBL4872206 | ↓ inhibits | Mechanistic | 1200.0 nM (IC50) | ChEMBL |
| N-OXALYLGLYCINE | ↓ inhibits | Mechanistic | 19700.0 nM (IC50) | ChEMBL |
| CHEMBL4851104 | ↓ inhibits | Mechanistic | 9400.0 nM (IC50) | ChEMBL |
| CHEMBL4855677 | ↓ inhibits | Mechanistic | 54800.0 nM (IC50) | ChEMBL |
| CHEMBL4872110 | ↓ inhibits | Mechanistic | 11000.0 nM (IC50) | ChEMBL |
| CHEMBL4860506 | ↓ inhibits | Mechanistic | 10500.0 nM (IC50) | ChEMBL |
| CHEMBL4870693 | ↓ inhibits | Mechanistic | 3420.0 nM (Kd) | ChEMBL |
| CHEMBL4859276 | ↓ inhibits | Mechanistic | 2050.0 nM (Kd) | ChEMBL |
| DEFEROXAMINE | ↓ inhibits | Mechanistic | 46000.0 nM (IC50) | ChEMBL |
| CHEMBL5193408 | ↓ inhibits | Mechanistic | 13000.0 nM (IC50) | ChEMBL |
| CHEMBL5205660 | ↓ inhibits | Mechanistic | 2300.0 nM (IC50) | ChEMBL |
| CHEMBL5199439 | ↓ inhibits | Mechanistic | 86600.0 nM (IC50) | ChEMBL |
| CHEMBL5177215 | ↓ inhibits | Mechanistic | 23900.0 nM (IC50) | ChEMBL |
| CHEMBL1230640 | ↓ inhibits | Mechanistic | 2270.0 nM (IC50) | ChEMBL |
| CHEMBL316034 | ↓ inhibits | Mechanistic | 5128.61 nM (IC50) | ChEMBL |
| CHEMBL3646117 | ↓ inhibits | Mechanistic | 18620.87 nM (IC50) | ChEMBL |
| CHEMBL4475458 | ↓ inhibits | Mechanistic | 5495.41 nM (IC50) | ChEMBL |
| VADADUSTAT | ↓ inhibits | Mechanistic | 5011.87 nM (IC50) | ChEMBL |
| CHEMBL1982368 | ↓ inhibits | Mechanistic | 3019.95 nM (IC50) | ChEMBL |
| CHEMBL1398529 | ↓ inhibits | Mechanistic | 1548.82 nM (IC50) | ChEMBL |
| PANOBINOSTAT | ↓ inhibits | Mechanistic | 3801.89 nM (IC50) | ChEMBL |
| CHEMBL1615211 | ↓ inhibits | Mechanistic | 12882.5 nM (IC50) | ChEMBL |
| CHEMBL1614745 | ↓ inhibits | Mechanistic | 15488.17 nM (IC50) | ChEMBL |
| CHEMBL92309 | ↑ activates | Mechanistic | 11481.54 nM (EC50) | ChEMBL |
| CHEMBL5527999 | ↓ inhibits | Mechanistic | 250.0 nM (IC50) | ChEMBL |
| CHEMBL5565375 | ↓ inhibits | Mechanistic | 250.0 nM (IC50) | ChEMBL |
| CHEMBL5557372 | ↓ inhibits | Mechanistic | 23988.33 nM (IC50) | ChEMBL |
Showing top 40 of 68 agents ranked by evidence tier.
Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.
Background: \- Cardiometabolic diseases are medical disorders that can occur together and affect the heart. They increase the risk of developing heart disease and diabetes. One disorder, psoriasis, is an inflammation that mostly affects the skin but can affect the entire body. Another disorder, ath...
This study will evaluate people with dyslipidemias - disorders that affect the fat content in the blood. Fats, or lipids, such as cholesterol and triglycerides, are carried in the blood in particles called lipoproteins. These particles are involved in causing blood vessel diseases that can lead to c...
The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero drug-coated balloon \[DCB\]) in the treatment of the femoropopliteal artery l...
Background: \- Genes are the instructions our body uses to function. Researchers can look for changes, or variants, in the genes. The goal of this study is to find new gene changes that lead to lipid disorders. Older research methods looked at one or a few genes at a time. Genomic sequencing looks ...
The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs pl...
This is a preliminary prospective observational study measuring change in lower extremity temperature in response to revascularization procedure. The main question this study aims to answer is: \- Are temperature measurements from a forward looking infrared (FLIR) camera of the lower extremity use...
Homozygous familial hypercholesterolemia is a rare inherited disease of metabolism. It occurs in less than 1 in 1 million people within the United States. Patients with the disease are typically children and young adults who develop heart disease early in life. Children less than age 5 years with th...
The main purpose of the study is to evaluate the efficacy of selnoflast compared with placebo in participants with atherosclerosis, at high-risk for major adverse cardiovascular event (MACE), who are currently on standard-of-care (SOC) therapy.
Chronic limb threatening ischemia (CLTI) represents the most advanced stage of peripheral arterial disease (PAD) and is characterized by ischemic rest pain, non-healing wounds, or ischemic gangrene. High-risk PAD populations including patients with end-stage renal disease and or diabetes also experi...
The primary objective of the ASA-3C trial is to evaluate the role of aspirin and high-intensity statin therapy, respectively, in individuals with severe coronary calcification (coronary calcium score ≥300) to prevent atherosclerotic cardiovascular disease (ASCVD) events with severe coronary calcific...
A double-blind randomized-controlled clinical trial is conducted in order to evaluate the impact of non-surgical periodontal treatment on endothelial dysfunction parameters in subjects with periodontitis and without any cardiovascular disease.
The prevalence of peripheral arterial disease is 12.2% in France. Intermittent claudication is the most common symtom of this disease. During physical exercise, such as walking, blood oxygen (O2) requirements increase. The development of atherosclerosis in the lower limbs, causes narrowing of the ar...
Background: \- Researchers are interested in studying individuals who have known or suspected metabolic, inflammatory or genetic diseases that may put them at a high risk for heart diseases or diseases of their blood vessels. Depending on the condition being studied, both affected and nonaffected i...
TACT3a is a double blind, placebo-controlled, randomized trial to test a novel therapy, edetate disodium-based chelation of environmentally acquired toxic metals, to reduce cardiovascular events including amputation in high-risk diabetic patients.
The goal of this clinical trial is to learn if UDP-003 is safe in healthy human participants and patients, assess the pharmacokinetics (PK)/pharmacodynamics (PD) of UDP-003 in healthy human participants and patients and its potential efficacy in patients. Researchers will compare UDP-003 to a place...
Searched directly from “Atherosclerosis” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 8-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."